This scan compares TB performance indicators and targets in Canada, the United States, the United Kingdom and Australia. This is a student project.
COMMENTARY: Yoav Keynan, MD and NCCID’s Scientific Lead COMMENT According to the WHO 2017 report, in 2016 globally, there were 600,000 new cases of tuberculosis with resistance to rifampicin, the most effective first-line drug, of which 490,000 cases had multidrug-resistant TB (MDR-TB), defined as resistance to rifampicin and isoniazid. Almost half (47%) of these cases…
An in-depth review and analysis of the model of latent tuberculosis infection management and promising treatment completion outcomes at BridgeCare Clinic in Winnipeg, Canada.
In this case study, we share the story of the success of BridgeCare Clinic, a model of integrated TB services for government-assisted refugees for its approach to improving latent tuberculosis infection (LTBI) treatment completion outcomes in priority populations.